A phase III randomised, double-blind, multicentre study to evaluate the safety and efficacy of 1592U89 (abacavir) in human immunodeficiency virus 1-infected patients with aquired immune deficiency syndrome dementia complex
Phase of Trial: Phase III
Latest Information Update: 30 Jul 2007
At a glance
- Drugs Abacavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 30 Jul 2007 The expected completion date for this trial is now 8 Jan 1998.
- 23 Jul 2007 New trial record.